Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 VaccineGlobeNewsWire • 05/04/20
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common StockGlobeNewsWire • 04/16/20
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase DeficiencyGlobeNewsWire • 04/13/20
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 VaccineGlobeNewsWire • 04/09/20
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation SystemGlobeNewsWire • 03/27/20
Arcturus Therapeutics Holdings, Inc. (ARCT) CEO Joseph Payne on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/11/20
Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 03/04/20
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™GlobeNewsWire • 03/04/20
Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development OfficerGlobeNewsWire • 01/08/20
Will Arcturus Therapeutics (ARCT) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/30/19
Arcturus Therapeutics (ARCT) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 10/08/19
Arcturus Therapeutics Holdings Inc (ARCT) President and CEO Joseph E Payne Bought $56,100 of SharesGuruFocus • 08/30/19
Arcturus Therapeutics Holdings Inc (ARCT) CFO Andy Sassine Bought $109,000 of SharesGuruFocus • 08/26/19
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/16/19